OpenURL Connection Search

Select item for more details and to access through your institution.

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.
Published in:
American Journal of Hematology, 2021, v. 96, n. 12, p. E457, doi. 10.1002/ajh.26363
By:
- Fürstenau, Moritz;
- Giza, Adam;
- Stumpf, Thomas;
- Robrecht, Sandra;
- Maurer, Christian;
- Linde, Hartmut;
- Jacobasch, Lutz;
- Dörfel, Steffen;
- Aldaoud, Ali;
- von Tresckow, Julia;
- Koenigsmann, Michael;
- Gaska, Tobias;
- Kaiser, Ulrich;
- Harich, Hanns‐Detlev;
- Fischer, Kirsten;
- Eichhorst, Barbara;
- Hallek, Michael;
- Fink, Anna‐Maria
Publication type:
Article
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).
Published in:
2020
By:
- Tintelnot, Joseph;
- Goekkurt, Eray;
- Binder, Mascha;
- Thuss-Patience, Peter;
- Lorenzen, Sylvie;
- Knorrenschild, Jorge Riera;
- Kretzschmar, Albrecht;
- Ettrich, Thomas;
- Lindig, Udo;
- Jacobasch, Lutz;
- Pink, Daniel;
- Al-Batran, Salah-Eddin;
- Hinke, Axel;
- Hegewisch-Becker, Susanna;
- Nilsson, Sven;
- Bokemeyer, Carsten;
- Stein, Alexander
Publication type:
journal article
Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.
Published in:
European Journal of Haematology, 2018, v. 101, n. 2, p. 208, doi. 10.1111/ejh.13096
By:
- Gattermann, Norbert;
- Coll, Rosa;
- Jacobasch, Lutz;
- Allameddine, Allameddine;
- Azmon, Amin;
- De Bonnett, Laurie;
- Bruederle, Andreas;
- Jie Jin
Publication type:
Article
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.
Published in:
Annals of Hematology, 2023, v. 102, n. 12, p. 3383, doi. 10.1007/s00277-023-05458-1
By:
- Koschmieder, Steffen;
- Isfort, Susanne;
- Schulte, Clemens;
- Jacobasch, Lutz;
- Geer, Thomas;
- Reiser, Marcel;
- Koenigsmann, Michael;
- Heinrich, Bernhard;
- Wehmeyer, Jürgen;
- von der Heyde, Eyck;
- Tesch, Hans;
- Gröschl, Benedikt;
- Bachhuber, Petra;
- Großer, Susanne;
- Pahl, Heike L.
Publication type:
Article
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.
Published in:
Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 10, p. 2693, doi. 10.1007/s00432-021-03855-5
By:
- Crodel, Carl C.;
- Jentsch-Ullrich, Kathleen;
- Reiser, Marcel;
- Jacobasch, Lutz;
- Sauer, Annette;
- Tesch, Hans;
- Ulshöfer, Thomas;
- Wunschel, Regine;
- Palandri, Francesca;
- Heidel, Florian H.
Publication type:
Article

Found: 5

Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia.

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2-positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217).

Effect of deferasirox + erythropoietin vs erythropoietin on erythroid response in Low/Int-1-risk MDS patients: Results of the phase II KALLISTO trial.

Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial.

Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia vera.